Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

764.80 -11.95 (-1.54%)
Streaming Delayed Price Updated: 11:04 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9 Next >
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
The S&P 500's 3 best 10-year performers are all in this industry
Given the critical role semiconductors play in the global economy, it’s no surprise that chipmakers have hauled in some serious profits over the past decade. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
MarketBeat Week in Review – 2/5 - 2/9
The markets continue to rise as investors come to grips with higher interest rates, but next week's inflation data may cool down the bullish momentum 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Monday Morning Trading
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
Eli Lilly's formula for success: Blending innovation with insight
Eli Lilly showcases its financial strength and strategic innovation through its Q4 2023 earnings and forward-looking growth initiatives. 
Via MarketBeat
Markets suddenly price Eli Lilly stock for a breakout on earnings
The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up 
Via MarketBeat
Topics Bonds Economy
Exposures Debt Markets Interest Rates
Eli Lilly and Company (NYSE: LLY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite 
Via MarketBeat
Topics Economy
Exposures Economy
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
AstraZeneca: Rebound in 2024 with double-digit earnings growth
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition 
Via MarketBeat
Exposures COVID-19
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
Via Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END 
Via FinancialNewsMedia
Where will S&P 500 go after new bullish levels?
Major indexes look resilient despite 2024's rocky start, getting support at key moving averages. Upcoming earnings could be catalysts in either direction. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Can Simply Good Foods ride the GLP-1 weight loss trend in 2024?
Simply Good Foods may be ready to breakout as the GLP-1 medication weight-loss trend is driving up sales for its Atkins and Quest Nutrition branded products 
Via MarketBeat
Merck, the Dow's hottest stock, gets set to report Q4 financials
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. 
Via MarketBeat
Topics Stocks
Exposures US Equities
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
Weight Watchers gains from Oprah’s GLP-1 weight-loss
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
LifeMD expands telehealth GLP-1weight-loss service with Medifast
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing 
Via MarketBeat
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
Exposures Product Safety
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage 
Via MarketBeat
Exposures Product Safety
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
These are the top sectors for blue chip growth in 2024
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains. 
Via MarketBeat
Topics Economy Intellectual Property
Exposures COVID-19 Intellectual Property Interest Rates
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Type 1 Diabetes Market Comprehensive Study Explores Huge Growth by Key Players DiaVacs, XOMA Corp., Biodel, Macrogenics
Type 1 Diabetes Market Growth 
Via SBWire
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.